secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001558370-22-007951
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q1 net loss $12.9M; reiterates FY2022 opex $55-60M; IMM-1-104 IND on track for Q3 2022
--------------------------------------------------------------------------------

- Net loss $12.9M ($0.49/share) vs $6.2M ($1.26/share) in Q1 2021; R&D $9.1M, G&A $4.0M.
- Cash $137.8M as of March 31, 2022; cash runway into Q3 2024.
- IMM-1-104 IND filing expected Q3 2022; first patient enrollment Phase 1 expected Q4 2022.
- IMM-6-415 IND filing expected 2023.
- FY2022 GAAP opex guidance $55-60M including non-cash stock-based comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/0001558370-22-007951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022007951/imrx-20220510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-007951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer